BIKTARVY® is a triple therapy STR that pairs the power of bictegravir with a trusted dual-NRTI backbone.1,2
BIKTARVY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of BIKTARVY.
DESCOVY, a component of BIKTARVY, is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients weighing at least 35 kg.
IMPORTANT SAFETY INFORMATION FOR BIKTARVY AND DESCOVY
BIKTARVY, the BIKTARVY Logo, DESCOVY, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks referenced herein are the property of their respective owners.
© 2020 Gilead Sciences, Inc. All rights reserved. BVYP0560 05/20